Published 08:09 IST, February 12th 2024
Australia’s CSL top loser on ASX 200 following failure of heart attack drug trial
The study did not meet its primary efficacy endpoint, leading to the absence of plans for a near-term regulatory filing, according to the company.
Australian shares | Image:
ASX
- Listen to this article
- 2 min read
Advertisement
08:09 IST, February 12th 2024